Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | UTRN | P46939 | 4/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.31 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21919003 | 0.90 | UTRN (0.31) | CEPT1SMN1; SMN2UTRN | |
| SCHEMBL20489671 | 0.83 | UTRN (0.35) | CEPT1SMN1; SMN2UTRNHDAC6CYP1A2 | |
| SCHEMBL18758899 | 0.83 | UTRN (0.33) | CEPT1UTRNHDAC6CYP1A2AHR | |
| SCHEMBL29603320 | 0.83 | UTRN (0.35) | CEPT1SMN1; SMN2UTRNHDAC6CYP1A2 | |
| SCHEMBL21810435 | 0.82 | CYP1A2 (0.30) | UTRNHDAC6CYP1A2AHR | |
| SCHEMBL21525980 | 0.82 | CYP1A2 (0.30) | UTRNHDAC6CYP1A2AHR | |
| SCHEMBL18760177 | 0.82 | UTRN (0.35) | CEPT1UTRNHDAC6CYP1A2AHR | |
| SCHEMBL29603454 | 0.82 | UTRN (0.35) | CEPT1UTRNHDAC6CYP1A2AHR | |
| SCHEMBL23120301 | 0.82 | HSPD1 (0.36) | CEPT1SMN1; SMN2UTRNHDAC6CYP1A2 | |
| SCHEMBL15858543 | 0.81 | UTRN (0.38) | UTRNHDAC6CYP1A2AHRCETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10856548-B2 | Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound or the salt, and method for using the insecticide | NIHON NOHYAKU CO., LTD. (JP) | 2020-12-08 | — | — | US | disclosed |
| US-20200085054-A1 | OXIME GROUP-CONTAINING CONDENSED HETEROCYCLIC COMPOUND OR SALT THEREOF, AGRICULTURAL AND HORTICULTURAL INSECTICIDE COMPRISING THE COMPOUND OR THE SALT, AND METHOD FOR USING THE INSECTICIDE | NIHON NOHYAKU CO., LTD. (JP) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200085054-A1 | OXIME GROUP-CONTAINING CONDENSED HETEROCYCLIC COMPOUND OR SALT THEREOF, AGRICULTURAL AND HORTICULTURAL INSECTICIDE COMPRISING THE COMPOUND OR THE SALT, AND METHOD FOR USING THE INSECTICIDE | OXSR1, CBR3, OSR1 | CEPT1 1548/4885SMN1; SMN2 3550/4885UTRN 4859/4885 |
| US-10856548-B2 | Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound or the salt, and method for using the insecticide | OXSR1, CBR3, OSR1 | CEPT1 1548/4885SMN1; SMN2 3550/4885UTRN 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.